Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica

Noriko Isobe, Tomomi Yonekawa, Takuya Matsushita, Katsuhisa Masaki, Satoshi Yoshimura, Jakub Fichna, Shu Chen, Jadwiga Furmaniak, Bernard Rees Smith, Jun Ichi Kira

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Neuromyelitis optica (NMO) is an inflammatory disease that selectively affects the optic nerves and spinal cord. The discovery of NMO-IgG targeting aquaporin-4 (AQP4) in NMO patients suggested that NMO is a distinct entity, with a fundamentally different etiology from that of multiple sclerosis (MS). Although NMO usually leads to grave disability because of the more severe tissue destruction compared with classical MS, there have been several reports describing a benign form of NMO over a long disease term. NMO-IgG/AQP4 antibodies show high specificity but medium sensitivity for NMO, while the clinical relevance of AQP4 antibody titers remains to be determined. We aimed to clarify the clinical relevance of AQP4 antibody levels determined by a bridging enzyme-linked immunosorbent assay in 38 patients with NMO or NMO spectrum disorder. The AQP4 antibody levels were higher in patients with optic neuritis (ON) than in those without ON (p = 0.0164). Among the 12 patients examined in a longitudinal study, four showed an increase in the ELISA values during some relapses, and eight showed no clear correlation between the ELISA values and relapse. Of the four patients who demonstrated a steady rise in the antibody levels over time, two patients had no concomitant relapses, despite elevation of the AQP4 antibody levels. We conclude that high AQP4 antibody levels are associated with the occurrence of ON, but that the antibody levels themselves are not closely correlated with the onset of relapse.

Original languageEnglish
Pages (from-to)997-1001
Number of pages5
JournalNeurochemical Research
Volume38
Issue number5
DOIs
Publication statusPublished - May 1 2013

Fingerprint

Aquaporin 4
Neuromyelitis Optica
Antibodies
Serum
Optics
Optic Neuritis
Recurrence
Enzyme-Linked Immunosorbent Assay
Immunoglobulin G
Multiple Sclerosis
Immunosorbents
Assays
Optic Nerve
Longitudinal Studies
Tissue
Spinal Cord

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica. / Isobe, Noriko; Yonekawa, Tomomi; Matsushita, Takuya; Masaki, Katsuhisa; Yoshimura, Satoshi; Fichna, Jakub; Chen, Shu; Furmaniak, Jadwiga; Smith, Bernard Rees; Kira, Jun Ichi.

In: Neurochemical Research, Vol. 38, No. 5, 01.05.2013, p. 997-1001.

Research output: Contribution to journalArticle

Isobe, Noriko ; Yonekawa, Tomomi ; Matsushita, Takuya ; Masaki, Katsuhisa ; Yoshimura, Satoshi ; Fichna, Jakub ; Chen, Shu ; Furmaniak, Jadwiga ; Smith, Bernard Rees ; Kira, Jun Ichi. / Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica. In: Neurochemical Research. 2013 ; Vol. 38, No. 5. pp. 997-1001.
@article{0157409bc2ae4c3e8517436241ac0471,
title = "Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica",
abstract = "Neuromyelitis optica (NMO) is an inflammatory disease that selectively affects the optic nerves and spinal cord. The discovery of NMO-IgG targeting aquaporin-4 (AQP4) in NMO patients suggested that NMO is a distinct entity, with a fundamentally different etiology from that of multiple sclerosis (MS). Although NMO usually leads to grave disability because of the more severe tissue destruction compared with classical MS, there have been several reports describing a benign form of NMO over a long disease term. NMO-IgG/AQP4 antibodies show high specificity but medium sensitivity for NMO, while the clinical relevance of AQP4 antibody titers remains to be determined. We aimed to clarify the clinical relevance of AQP4 antibody levels determined by a bridging enzyme-linked immunosorbent assay in 38 patients with NMO or NMO spectrum disorder. The AQP4 antibody levels were higher in patients with optic neuritis (ON) than in those without ON (p = 0.0164). Among the 12 patients examined in a longitudinal study, four showed an increase in the ELISA values during some relapses, and eight showed no clear correlation between the ELISA values and relapse. Of the four patients who demonstrated a steady rise in the antibody levels over time, two patients had no concomitant relapses, despite elevation of the AQP4 antibody levels. We conclude that high AQP4 antibody levels are associated with the occurrence of ON, but that the antibody levels themselves are not closely correlated with the onset of relapse.",
author = "Noriko Isobe and Tomomi Yonekawa and Takuya Matsushita and Katsuhisa Masaki and Satoshi Yoshimura and Jakub Fichna and Shu Chen and Jadwiga Furmaniak and Smith, {Bernard Rees} and Kira, {Jun Ichi}",
year = "2013",
month = "5",
day = "1",
doi = "10.1007/s11064-013-1009-0",
language = "English",
volume = "38",
pages = "997--1001",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica

AU - Isobe, Noriko

AU - Yonekawa, Tomomi

AU - Matsushita, Takuya

AU - Masaki, Katsuhisa

AU - Yoshimura, Satoshi

AU - Fichna, Jakub

AU - Chen, Shu

AU - Furmaniak, Jadwiga

AU - Smith, Bernard Rees

AU - Kira, Jun Ichi

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Neuromyelitis optica (NMO) is an inflammatory disease that selectively affects the optic nerves and spinal cord. The discovery of NMO-IgG targeting aquaporin-4 (AQP4) in NMO patients suggested that NMO is a distinct entity, with a fundamentally different etiology from that of multiple sclerosis (MS). Although NMO usually leads to grave disability because of the more severe tissue destruction compared with classical MS, there have been several reports describing a benign form of NMO over a long disease term. NMO-IgG/AQP4 antibodies show high specificity but medium sensitivity for NMO, while the clinical relevance of AQP4 antibody titers remains to be determined. We aimed to clarify the clinical relevance of AQP4 antibody levels determined by a bridging enzyme-linked immunosorbent assay in 38 patients with NMO or NMO spectrum disorder. The AQP4 antibody levels were higher in patients with optic neuritis (ON) than in those without ON (p = 0.0164). Among the 12 patients examined in a longitudinal study, four showed an increase in the ELISA values during some relapses, and eight showed no clear correlation between the ELISA values and relapse. Of the four patients who demonstrated a steady rise in the antibody levels over time, two patients had no concomitant relapses, despite elevation of the AQP4 antibody levels. We conclude that high AQP4 antibody levels are associated with the occurrence of ON, but that the antibody levels themselves are not closely correlated with the onset of relapse.

AB - Neuromyelitis optica (NMO) is an inflammatory disease that selectively affects the optic nerves and spinal cord. The discovery of NMO-IgG targeting aquaporin-4 (AQP4) in NMO patients suggested that NMO is a distinct entity, with a fundamentally different etiology from that of multiple sclerosis (MS). Although NMO usually leads to grave disability because of the more severe tissue destruction compared with classical MS, there have been several reports describing a benign form of NMO over a long disease term. NMO-IgG/AQP4 antibodies show high specificity but medium sensitivity for NMO, while the clinical relevance of AQP4 antibody titers remains to be determined. We aimed to clarify the clinical relevance of AQP4 antibody levels determined by a bridging enzyme-linked immunosorbent assay in 38 patients with NMO or NMO spectrum disorder. The AQP4 antibody levels were higher in patients with optic neuritis (ON) than in those without ON (p = 0.0164). Among the 12 patients examined in a longitudinal study, four showed an increase in the ELISA values during some relapses, and eight showed no clear correlation between the ELISA values and relapse. Of the four patients who demonstrated a steady rise in the antibody levels over time, two patients had no concomitant relapses, despite elevation of the AQP4 antibody levels. We conclude that high AQP4 antibody levels are associated with the occurrence of ON, but that the antibody levels themselves are not closely correlated with the onset of relapse.

UR - http://www.scopus.com/inward/record.url?scp=84876166846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876166846&partnerID=8YFLogxK

U2 - 10.1007/s11064-013-1009-0

DO - 10.1007/s11064-013-1009-0

M3 - Article

C2 - 23456674

AN - SCOPUS:84876166846

VL - 38

SP - 997

EP - 1001

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 5

ER -